Porton Advanced Solutions Ltd. and Yinjia (Shanghai) Biosciences Co., Ltd. have announced a strategic partnership to accelerate the development and commercialization of cell and gene therapy (CGT). Porton Advanced is an end-to-end gene and cell therapy service provider, while Yinjia Biosciences specializes in high-quality core protein raw materials and companion diagnostics products for adjuvant therapies. Under the partnership, Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Porton Advanced will leverage these resources to enhance its CGT CDMO and accelerate the development of innovative CGT therapeutics to address clinical needs and empower global partners. "We are glad to establish a strategic partnership with Yinjia Biosciences. This strategic partnership will strengthen Porton Advanced's CGT CDMO and accelerate the development of innovative CGT therapeutics to deliver life-changing benefits to patients," said Dr. Wang Yangzhou, CEO of Porton Advanced. "We are excited to partner with Porton Advanced to apply our products in other areas and create new possibilities for us to meet more client needs," said Dr. Wu Yifei, Chairman and CEO of Yinjia Biosciences.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!